会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT
    • 用于PDT的不对称中间取代的PORPHYRINS和CHLORIN的方法和应用
    • US20110206613A1
    • 2011-08-25
    • US13119907
    • 2009-09-17
    • Arno WieheDaniel AicherChristian B .W. StarkVolker AlbrechiSusanna Gräfe
    • Arno WieheDaniel AicherChristian B .W. StarkVolker AlbrechiSusanna Gräfe
    • A61K49/00C07D487/22A61K31/409C07K16/00C07K2/00C07H15/26A61K31/7056A61P19/02A61P29/00A61P43/00
    • C07D487/22C07H15/26
    • Biologically active compounds are provided that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. In another embodiment a method to reductively cleave the osmate(VI)ester avoiding the use of gaseous H2S is provided. In another embodiment substituents are identified that via their steric and/or electronic influence direct the dihydroxylation or reduction with diimine so that one isomer is favored. Another embodiment consists of formulate the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like solubility problems or delayed pharmacokinetics of the tetrapyrrole systems.
    • 提供了可用作诊断和治疗应用的光敏剂的生物活性化合物,特别是用于癌症,感染和其它过度增生性疾病的PDT,荧光诊断和PDT治疗非肿瘤适应症如关节炎,炎性疾病,病毒或细菌 感染,皮肤病学,眼科学或泌尿系统疾病,以及提供以药物质量获得它们的方法。 一个实施方案由合成具有定义的内消旋取代基排列的卟啉的方法组成,然后通过二羟基化或还原将该卟啉体系转化为二氢卟酚体系,并且如果形成多于一种的异构体,则通过色谱法分离,或者在正常或反向 相二氧化硅。 在另一个实施方案中,选择卟啉上的取代基以指导还原或二羟基化为二氢卟酚,从而选择性地形成某种异构体。 另一个实施方案是提供具有更高膜亲和力和增加的PDT功效的两亲化合物。 在另一个实施方案中,提供了避免使用气态H 2 S的还原性裂解锇酸酯(VI)酯的方法。 在另一个实施方案中,鉴定了取代基,通过它们的空间和/或电子影响直接使二羟基化或还原与二亚胺,使得一种异构体是有利的。 另一个实施方案包括将所需的异构体配制成待注射的脂质体制剂,避免不期望的作用,如四吡咯体系的溶解性问题或延迟的药代动力学。
    • 2. 发明授权
    • Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT
    • 用于PDT的不对称内消旋卟啉和二氢卟酚的方法和应用
    • US09315510B2
    • 2016-04-19
    • US13119907
    • 2009-09-17
    • Arno WieheDaniel AicherChristian B. W. StarkVolker AlbrechtSusanna Gräfe
    • Arno WieheDaniel AicherChristian B. W. StarkVolker AlbrechtSusanna Gräfe
    • A61K31/409C07D487/22C07H15/26
    • C07D487/22C07H15/26
    • Biologically active compounds are provided that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. In another embodiment a method to reductively cleave the osmate(VI)ester avoiding the use of gaseous H2S is provided. In another embodiment substituents are identified that via their steric and/or electronic influence direct the dihydroxylation or reduction with diimine so that one isomer is favored. Another embodiment consists of formulate the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like solubility problems or delayed pharmacokinetics of the tetrapyrrole systems.
    • 提供了可用作诊断和治疗应用的光敏剂的生物活性化合物,特别是用于癌症,感染和其它过度增生性疾病的PDT,荧光诊断和PDT治疗非肿瘤适应症如关节炎,炎性疾病,病毒或细菌 感染,皮肤病学,眼科学或泌尿系统疾病,以及提供以药物质量获得它们的方法。 一个实施方案由合成具有定义的内消旋取代基排列的卟啉的方法组成,然后通过二羟基化或还原将该卟啉体系转化为二氢卟酚体系,并且如果形成多于一种的异构体,则通过色谱法分离,或者在正常或反向 相二氧化硅。 在另一个实施方案中,选择卟啉上的取代基以指导还原或二羟基化为二氢卟酚,从而选择性地形成某种异构体。 另一个实施方案是提供具有更高膜亲和力和增加的PDT功效的两亲化合物。 在另一个实施方案中,提供了避免使用气态H 2 S的还原性裂解锇酸酯(VI)酯的方法。 在另一个实施方案中,鉴定了取代基,通过它们的空间和/或电子影响直接使二羟基化或还原与二亚胺,使得一种异构体是有利的。 另一个实施方案包括将所需的异构体配制成待注射的脂质体制剂,避免不期望的作用,如四吡咯体系的溶解性问题或延迟的药代动力学。
    • 4. 发明申请
    • APPLICATION OF BETA-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT
    • 用于PDT的功能化二羟基氯化物的应用
    • US20130041307A1
    • 2013-02-14
    • US13208917
    • 2011-08-12
    • Daniel AicherArno WieheChristian B. W. StarkVolker AlbrechrSusanna Gräfe
    • Daniel AicherArno WieheChristian B. W. StarkVolker AlbrechrSusanna Gräfe
    • A61M37/00A61K39/395A61K31/407A61K9/127C07D487/22A61K38/00
    • C07D487/22A61K41/0071A61K49/0036
    • The present invention provides methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. An embodiment of the present invention consists of a method to synthesize diketo-chlorins as precursors. In yet another embodiment these precursors are converted to β-functionalized hydroxy- and dihydroxy-chlorins. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. Another embodiment consists of the formulation of the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like precipitation at the injection site or delayed pharmacokinetics of the tetrapyrrole systems.
    • 本发明提供了获得可用作诊断和治疗应用的光敏剂的生物活性化合物的方法,特别是用于癌症,感染和其它过度增殖性疾病的PDT,荧光诊断和PDT治疗非肿瘤适应症如关节炎,炎症 疾病,病毒或细菌感染,皮肤病学,眼科学或泌尿系统疾病。 本发明的一个实施方案由合成二酮二氢卟酚作为前体的方法组成。 在另一个实施方案中,这些前体转化为官能化的羟基和二羟基二氢卟酚。 另一个实施方案是提供具有更高膜亲和力和增加的PDT功效的两亲化合物。 另一个实施方案包括将所需异构体配制成待注射的脂质体制剂,以避免不期望的作用,如注射部位的沉淀或四吡咯体系的延迟药代动力学。